¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"latent iron-binding capacity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • latent phage
    ÀáÀçÆÄÁö
  • latent phase
    1. ÀáÀç±â 2. Àẹ±â
  • latent porphyria
    ÀáÀçÆ÷¸£ÇǸ°Áõ
  • latent schizophrenia
    ÀáÀçÁ¤½ÅºÐ¿­º´
  • latent stage
    ÀáÀç±â, Àẹ±â
  • latent strabismus
    Àẹ»ç½Ã
  • latent syphilis
    Àẹ¸Åµ¶
  • latent tetany
    ÀẹÅן´Ï
  • latent time
    Àẹ½Ã°£
  • latent tuberculosis
    Àẹ°áÇÙ
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • adsorption capacity
    ÈíÂø´É
  • agglutinating capacity
    ÀÀÁý´É
  • bladder capacity
    ¹æ±¤¿ëÀû
  • breathing capacity
    È£Èí·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • total lung capacity
    ÃÑÆó¿ë·®, ¿ÂÇãÆÄ¿ë·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • latent period
    Àẹ±â
  • latent phage
    ÀáÀçÆÄÁö
  • latent porphyria
    ÀáÀçÆ÷¸£ÇǸ°Áõ
  • latent schizophrenia
    ÀáÀçÁ¤½ÅºÐ¿­º´
  • latent stage
    Àẹ±â
  • latent strabismus
    Àẹ»ç½Ã
  • latent syphilis
    Àẹ¸Åµ¶
  • latent tetany
    Àẹ°­Á÷
  • latent time
    Àẹ½Ã°£
  • latent tuberculosis
    Àẹ°áÇÙ
  • adsorption capacity
    ÈíÂø´É
  • agglutinating capacity
    ÀÀÁý´É
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • breathing capacity
    È£Èí¿ëÀû
  • buffering capacity
    ¿ÏÃæ´É
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inspiratory capacity
    Èí½Ä¿ë·®, Èí±â¿ëÀû.
  • inspiratory capacity
    Èí½Ä¿ë·®(ýåãÓé»Õá), Èí±â¿ëÀû(ýåѨé»îÝ) .
  • inspiratory capacity
    Èí½Ä¿ë·®,Èí±â¿ëÀû
  • inspiratory vital capacity
    Èí±âÆóȰ·®(ýåѨøËüÀÕá).
  • inspiratory vital capacity
    Èí±âÆóȰ·®.
  • predicted vital capacity
    ¿¹ÃøÆóȰ·®(çãö´øËüÀåÖ).
  • pulmonary diffusing capacity
    ÆóÈ®»ê´É(·Â)(øËüªß¤Òöæ³).
  • pulmonary ventilatory capacity
    Æóȯ±â¿ë·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • latent epilepsy
    Àẹ°£Áú(íÖÜÑÊÖòð).
  • latent finger-print
    ÇöÀåÁö¹®(úÞíÞò¦Ú£).
  • latent gout
    ÀáÀ缺 Åëdz(íÖî¤àõ÷Ôù¦).
  • latent heat
    Àá¿­(íÖæð).
  • latent heat
    Àá¿­(ËöËç).
  • latent heat of fusion
    À¶ÇØ(ë×ú°)Àá¿­.
  • latent hypermetropia
    Àẹ¿ø½Ã
  • latent hyperopia
    Àẹ¿ø½Ã
  • latent infection
    Àẹ°¨¿°(íÖÜÑÊïæø).
  • latent infection
    Àẹ°¨¿°, ÀáÀç°¨¿°, È޸鰨¿°
  • latent jaundice
    ÀáÀ缺 Ȳ´Þ(íÖî¤àõüÜÓ¸).
  • latent microbism
    Àẹ°¨¿°(ÊÙ˧Ëç).
  • latent nystagmus
    Àẹ¾ÈÁø
  • latent nystagmus
    Àẹ¾ÈÁø(¡­äÑòè).
  • latent period
    Àẹ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MBC male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ...
PWC peak work capacity; physical work capacity
TVC timed vital capacity; total viable cells; total volume capacity; transvaginal cone; triple voiding c...
ANLI antibody-negative with latent infection
CLV cassava latent virus; constant linear velocity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LMP1 Latent infection membrane protein 1
LMP1 Latent membrane protein
LMP-2A Latent membrane protein 2A
PLMVd Peach latent mosaic viroid
PLS Projections to Latent Structures
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • latent factor
    ÀáÀçÀû ¿ä¼Ò
  • latent finger-print
    ÇöÀå Áö¹®
    »ç°Ç ÇöÀå¿¡ ³²¾ÆÀÖ´Â Áö¹®.
  • latent heat of fusion
    À¶ÇØ Àá¿­
    ¹°ÁúÀÌ ³ì´Â °úÁ¤¿¡¼­ ¿ÂµµÀÇ º¯È­¸¦ ¼ö¹ÝÇÏÁö ¾Ê°í Èí¼ö ¶Ç´Â ¹æÃâµÇ´Â ¿­·®.
  • latent image
    ˇȗ
    »çÁø¿¡¼­, ³ëÃâÇÑ ÈÄ ¾ÆÁ÷ Çö»óÇÏÁö ¾ÊÀº Çʸ§ÀÇ °¨±¤¸· °¡¿îµ¥ ÀÖ´Â ÇÇ»çüÀÇ ¿µ»ó.
  • latent myofascial trigger point
    ÀáÀ缺 ±Ù¸· ¹ßÅëÁ¡
    ÃËÁø¿¡ ÀÇÇØ ÅëÁõÀÌ ³ªÅ¸³ª´Â °ÍÀ» Æ÷ÇÔÇÏ¿© Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡ÀÇ ¸ðµç Ư¼ºÀ» °¡ÁöÁö¸¸ Àڹ߼ºÀÇ ÀÓ»óÀû ÅëÁõÀ̳ª Áõ»óÀÇ ¿øÀÎÀÌ µÇÁö´Â ¾Ê´Â ±Ù¸· ¹ßÅëÁ¡.
  • latent period
    Àẹ±â, Àẹ½Ã, ÀáÀڱؽÃ, Àẹ ±â°£
    ¿Ü°ü»ó ºÒȰ¼ºÈ­ µÈ ±â°£. Á¶Á÷ÀÌ À¯ÇØ ¹°Áú¿¡ ³ëÃâ µÈ °Í°ú ¹ÝÀÀÀÌ ÀϾ±â±îÁöÀÇ »çÀÌ ¶Ç´Â Áï°¢ÀûÀÎ Àڱذú ¹ÝÀÀÀÇ ½ÃÀÛ »çÀÌÀÇ ±â°£.
  • latent prostatic cancer
    Àü¸³»ù ÀáÀç ¾Ï
  • latent schizophrenia
    Àẹ ºÐ¿­º´
    1. Á¤½Åº´ÀûÀÎ Á¤½ÅºÐ¿­º´ÀÇ ±â¿Õ·ÂÀº ¾øÀ¸³ª Á¤½ÅºÐ¿­º´¿¡ °É¸± °¨¼ö¼ºÀÌ ÀÖ´Â °Í. 2. Á¤½ÅºÐ¿­ÁõÀÇ ±âº»ÀûÀÎ Áõ»óÀº Á¸ÀçÇϰí ÀÖÀ¸³ª ºÐ¸íÇÑ Á¤½Åº´ Áõ»óÀ¸·Î Ç¥¸éÈ­Çϰųª »çȸ»ýȰÀÇ ºÎÀûÀÀÀ» ÃÊ·¡ÇÏÁö ¾Ê´Â °Í.
  • latent state
    ÀáÀç »óÅÂ
    Àẹ±âÀÇ ±ÕÀÇ »óÅÂ. ±Õ ÀÚ½ÅÀÇ º´Àû Ư¼ºÀ» ¹ßÈÖÇÏÁö ¸øÇϰí ÀÖ´Â »óÅÂ.
  • latent trigger point
    ÀáÀ缺 ¹ßÅëÁ¡
  • latent zone
    Àẹ´ë
    ¼¼±ÕÀÇ ÀÏ»ý¿¡¼­ Àẹ±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
hospital bed capacity The number of beds which a hospital has been designed and constructed to contain. It may also refer to the number of beds set up and staffed for use.
(12 Dec 1998)
specific heat capacity <chemistry> The amount of energy required to raise the temperature of one gram of a substance by one degree Celsius (or Kelvin).
(09 Jan 1998)
diffusing capacity The amount of oxygen taken up by pulmonary capillary blood per minute per unit average oxygen pressure gradient between alveolar gas and pulmonary capillary blood; units are: ml/min/mm Hg; also applied to other gases such as carbon monoxide.
(05 Mar 2000)
inspiratory capacity The maximum volume of air that can be inspired after reaching the end of a normal, quiet expiration. It is the sum of the tidal volume and the inspiratory reserve volume. Common abbreviation is ic.
(12 Dec 1998)
iron-binding capacity The capacity of iron-binding protein in serum (transferrin) to bind serum iron.
(05 Mar 2000)
oxygen capacity The maximum quantity of oxygen that will combine chemically with the haemoglobin in a unit volume of blood; normally it amounts to 1.34 ml of O2 per gm of Hb or 20 ml of O2 per 100 ml of blood.
(05 Mar 2000)
thermal capacity <chemistry> The amount of energy required to raise the temperature of an object by one degree Celsius (or Kelvin), it is represented by the symbol C and is given in units of J/K.
(09 Jan 1998)
total iron binding capacity <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream.
Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera.
Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements.
Acronym: TIBC
(12 Jan 1998)
total lung capacity The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: vital capacity plus residual volume; inspiratory capacity plus functional residual capacity; tidal volume plus inspiratory reserve volume plus functional residual capacity; tidal volume plus inspiratory reserve volume plus expiratory reserve volume plus residual volume.
(12 Dec 1998)
forced vital capacity Vital capacity measured with the subject exhaling as rapidly as possible; data relating volume, expiratory flow, and time form the basis for other pulmonary function tests, e.g., flow-volume curve, forced expiratory volume, forced expiratory time, forced expiratory flow.
(05 Mar 2000)
functional residual capacity The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc.
(12 Dec 1998)
early latent syphilis Infection with Treponema pallidum, the organism of syphilis, after the primary and secondary phases have subsided, during the first year after infection, before any manifestations of tertiary syphilis have appeared.
(05 Mar 2000)
late latent syphilis Usually infectious in pregnant women only, who may pass the infection on to the foetus.
(05 Mar 2000)
latent Dormant. A state that some cancer cells might assume. (Opp: growing or active).
(16 Dec 1997)
latent adrenocortical insufficiency Adrenocortical insufficiency not clinically evident but which can become severe if a sudden stress, such as an intercurrent acute illness, develops.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á